Market closedNon-fractional
Viracta Therapeutics/VIRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Viracta Therapeutics
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Ticker
VIRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cardiff, United States
Employees
40
Website
www.viracta.com
VIRX Metrics
BasicAdvanced
$19M
Market cap
-
P/E ratio
-$1.24
EPS
0.39
Beta
-
Dividend rate
Price and volume
Market cap
$19M
Beta
0.39
Financial strength
Current ratio
1.354
Quick ratio
1.308
Total debt to equity
170.19
Interest coverage (TTM)
-14.22%
Management effectiveness
Return on assets (TTM)
-51.49%
Return on equity (TTM)
-154.33%
Valuation
Price to book
3.41
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
-0.516
Growth
Earnings per share change (TTM)
-7.69%
3-year earnings per share growth (CAGR)
-64.07%
What the Analysts think about VIRX
Analyst Ratings
Majority rating from 4 analysts.
VIRX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$9.1M
-33.58%
Profit margin
0.00%
NaN%
VIRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.33
-$0.35
-$0.23
-
Expected
-$0.29
-$0.31
-$0.31
-$0.35
-$0.36
Surprise
10.34%
8.20%
12.90%
-34.75%
-
VIRX News
AllArticlesVideos
Viracta Therapeutics Announces New Employment Inducement Grants
GlobeNewsWire·2 months ago
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
GlobeNewsWire·2 months ago
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viracta Therapeutics stock?
Viracta Therapeutics (VIRX) has a market cap of $19M as of July 27, 2024.
What is the P/E ratio for Viracta Therapeutics stock?
The price to earnings (P/E) ratio for Viracta Therapeutics (VIRX) stock is 0 as of July 27, 2024.
Does Viracta Therapeutics stock pay dividends?
No, Viracta Therapeutics (VIRX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Viracta Therapeutics dividend payment date?
Viracta Therapeutics (VIRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viracta Therapeutics?
Viracta Therapeutics (VIRX) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Viracta Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.